Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
24.28
-0.33 (-1.34%)
At close: Apr 23, 2026, 4:00 PM EDT
24.36
+0.08 (0.33%)
Pre-market: Apr 24, 2026, 9:04 AM EDT

Ultragenyx Pharmaceutical Revenue

In the year 2025, Ultragenyx Pharmaceutical had annual revenue of $673.00M with 20.18% growth. Ultragenyx Pharmaceutical had revenue of $207.28M in the quarter ending December 31, 2025, with 25.89% growth.

Revenue (ttm)
$673.00M
Revenue Growth
+20.18%
P/S Ratio
3.54
Revenue / Employee
$490,883
Employees
1,371
Market Cap
2.38B

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 2025673.00M113.00M20.18%
Dec 31, 2024560.00M126.00M29.03%
Dec 31, 2023434.00M70.67M19.45%
Dec 31, 2022363.33M11.92M3.39%
Dec 31, 2021351.41M80.38M29.66%
Dec 31, 2020271.03M167.32M161.32%
Dec 31, 2019103.71M52.22M101.41%
Dec 31, 201851.50M48.88M1,871.48%
Dec 31, 20172.61M2.48M1,863.91%
Dec 31, 2016133.00K--
Dec 31, 2015---
Dec 31, 2014---
Dec 31, 2013---
Dec 31, 2012---
Dec 31, 2011---

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
ADMA Biologics510.17M
Zai Lab460.16M
Tarsus Pharmaceuticals451.36M
Day One Biopharmaceuticals158.18M
Immunome6.94M
Revenue Rankings